Allergy Denial Patterns
Allergy and immunology practices face denial rates of 7% to 12%, higher than most office-based specialties, because of the procedural volume, biologic medication requirements, and payer-specific testing limits that create multiple denial triggers per encounter. A single testing visit denied for medical necessity can represent $200 to $500 in lost revenue. Biologic denials can exceed $3,000 per occurrence. The financial impact of allergy denials is disproportionate to the denial count because of the high per-claim value of testing and drug claims.
Denial Reason 1: Test Frequency and Panel Size Limits
Many payers impose limits on allergy testing frequency and panel size. Common restrictions include: no more than one comprehensive panel per 12 months, a maximum of 60 to 80 percutaneous tests per session, and intradermal testing only after negative percutaneous results for the same allergens. Claims exceeding these limits are denied under frequency or benefit maximum edits.
Prevention requires knowing each major payer testing policy before the encounter. If a payer limits percutaneous tests to 60 per session, plan the testing panel to stay within that limit or obtain prior authorization for expanded testing. Document the clinical rationale for retesting within 12 months (new symptom onset, environmental change, treatment modification) to support appeals when frequency denials occur.
Denial Reason 2: Panel Bundling of 86003 and 86005
In vitro allergy testing uses 86003 (allergen-specific IgE, each allergen) and 86005 (allergen-specific IgE, multi-allergen screen). Some practices bill 86003 for individual allergens when the lab performed a multi-allergen panel that should be coded as 86005 followed by individual 86003 codes for reflexed positives. Payers bundle or deny claims when 86003 is billed for all allergens in a panel that was ordered as a multi-allergen screen.
To prevent bundling denials, match the billing to the actual test methodology. If the lab runs a multi-allergen screen (ImmunoCAP panel, component testing panel), bill 86005 for the screen and 86003 only for individually ordered follow-up allergens. Review lab reports to confirm whether testing was performed as individual assays or as a panel before assigning codes.
Denial Reason 3: Biologic Authorization Failures
Biologic denials are the most expensive allergy denial category. Omalizumab, dupilumab, and mepolizumab all require prior authorization, and denials occur for: expired PA (biologics typically require annual renewal), dosing changes not covered by the original PA, missing or outdated step therapy documentation, and failure to submit required lab values (IgE levels, eosinophil counts).
Prevention requires a PA tracking system that alerts the practice 30 days before PA expiration, flags any dosing change that may require PA modification, and maintains a current file of step therapy documentation and lab results for each biologic patient. Assign a dedicated staff member to biologic PA management. The revenue at stake ($1,000 to $3,000 per dose) justifies the staffing investment.
Denial Reason 4: Medical Necessity for Allergy Testing
Payers deny allergy testing claims when the diagnosis does not support the testing ordered. A claim for 80 percutaneous allergy tests with a diagnosis of “allergic rhinitis, unspecified” (J30.9) may be denied because the payer requires specific symptom documentation to justify the scope of testing. More specific diagnoses (J30.1 allergic rhinitis due to pollen, J30.2 other seasonal allergic rhinitis, L20.9 atopic dermatitis) paired with a documented history of symptom duration, severity, and failed empiric treatment strengthen medical necessity.
Document the clinical decision-making that led to testing: “Patient presents with 18 months of perennial nasal congestion, sneezing, and clear rhinorrhea unresponsive to over-the-counter antihistamines and nasal steroids. Testing is indicated to identify specific allergens for targeted avoidance counseling and potential immunotherapy.” This level of documentation supports medical necessity on appeal.
Denial Reason 5: Immunotherapy Visit Limits
Some payers cap the number of immunotherapy injection visits per calendar year or per treatment course. Common limits include 52 visits per year (weekly) during build-up and 12 to 15 visits per year during maintenance. Claims exceeding these limits are denied, and the practice must either appeal with clinical justification or absorb the cost. Track each patient injection count against their payer limit throughout the year.